Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Therapy recently approved in Canada under the brand name KORSUVA
Syngene's collaboration with Zoetis started in 2011
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Subscribe To Our Newsletter & Stay Updated
